Kyowa Hakko Kirin said on October 6 that it has called off the development of the c-MET inhibitor tivantinib (ARQ197) after the company failed to yield positive results from any of its studies covering multiple tumor types. In 2007, Kyowa…
To read the full story
Related Article
- Tivantinib Fails Japan PIII Trial for HCC: Kyowa Kirin
March 28, 2017
- In Yet Another Setback, Daiichi Sankyo’s Tivantinib Fails Liver Cancer PIII
February 21, 2017
BUSINESS
- Leqembi Iqlik Now Available for Alzheimer’s Initiation Use in US
August 25, 2026
- FDA Puts Regenxbio’s MPS II Gene Therapy Back on Clinical Hold
August 25, 2026
- Toho Builds Alternative Drug Delivery Options for Disaster Readiness
August 25, 2026
- OB/GYN Sees Abrysvo Becoming Part of Prenatal Care as NIP Drives Uptake
August 25, 2026
- Daiichi Sankyo Taps Ken Keller as New Commercial Chief in Global Revamp
August 25, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…





